Cipher Pharmaceuticals (CPHR) Given Daily Media Sentiment Rating of 0.05

News articles about Cipher Pharmaceuticals (NASDAQ:CPHR) (TSE:CPH) have been trending somewhat positive on Saturday, Accern Sentiment reports. The research group scores the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cipher Pharmaceuticals earned a news impact score of 0.05 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 44.4446637112034 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Cipher Pharmaceuticals (CPHR) opened at 2.99 on Friday. Cipher Pharmaceuticals has a 12-month low of $2.55 and a 12-month high of $4.81. The company’s 50-day moving average is $3.02 and its 200 day moving average is $3.00.

TRADEMARK VIOLATION WARNING: “Cipher Pharmaceuticals (CPHR) Given Daily Media Sentiment Rating of 0.05” was posted by BNB Daily and is owned by of BNB Daily. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc is a specialty pharmaceutical dermatology company. The Company has a portfolio of commercial and late-stage products. It operates in the specialty pharmaceuticals segment. It acquires products and compounds for treatment of various medical needs. Its commercial product portfolio includes ABSORICA; SITAVIG; NUVAIL; BIONECT; CLN8; INOVA; PRO:12 MOUSSE; AL12; LOTION UMECTA; ACLARO; EPURIS; VANIQA; ACTIKERALL; BETEFLAM; LIPOFEN; CONZIP, and DURELA.

Insider Buying and Selling by Quarter for Cipher Pharmaceuticals (NASDAQ:CPHR)

Receive News & Ratings for Cipher Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals Inc and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply